BASILEA N |
Date/Time | / |
Chg. / Chg.(%) | - / |
Bid | - |
Ask | - |
Open | - |
Previous Close | - |
High | - |
Low | - |
Volume [CHF] | - |
Volume [Units] | |
Price fixings | |
ISIN | CH0011432447 |
Security | BSLN |
Exchange | SIX Swiss Exchange |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 49.600 | ![]() |
24,766 |
London Domes.. | 49.80 | ![]() |
4,497 |
Cboe Europe .. | 49.55 | ![]() |
2,060 |
Cboe Europe .. | 49.55 | ![]() |
595 |
Turquoise | 49.50 | ![]() |
289 |
Lang & Schwa.. | 49.65 | ![]() |
|
Nasdaq Other.. | 52.0000 | 50 | |
München | 32.300 | 0 | |
TradeGate | 30.300 | 0 | |
EUREX | Options |
News
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
03/08/2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
02/15/2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
01/24/2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
01/13/2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
01/11/2022 / 07:15 - GlobeNewswire